JP2019504865A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504865A5
JP2019504865A5 JP2018542754A JP2018542754A JP2019504865A5 JP 2019504865 A5 JP2019504865 A5 JP 2019504865A5 JP 2018542754 A JP2018542754 A JP 2018542754A JP 2018542754 A JP2018542754 A JP 2018542754A JP 2019504865 A5 JP2019504865 A5 JP 2019504865A5
Authority
JP
Japan
Prior art keywords
ethanol
room temperature
solution
dihydrophthalazine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018542754A
Other languages
English (en)
Japanese (ja)
Other versions
JP6949856B2 (ja
JP2019504865A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/000209 external-priority patent/WO2017140422A1/en
Publication of JP2019504865A publication Critical patent/JP2019504865A/ja
Publication of JP2019504865A5 publication Critical patent/JP2019504865A5/ja
Application granted granted Critical
Publication of JP6949856B2 publication Critical patent/JP6949856B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018542754A 2016-02-16 2017-02-15 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンの結晶形の製造方法 Active JP6949856B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16000380.2 2016-02-16
EP16000380 2016-02-16
PCT/EP2017/000209 WO2017140422A1 (en) 2016-02-16 2017-02-15 Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

Publications (3)

Publication Number Publication Date
JP2019504865A JP2019504865A (ja) 2019-02-21
JP2019504865A5 true JP2019504865A5 (enExample) 2020-03-26
JP6949856B2 JP6949856B2 (ja) 2021-10-13

Family

ID=55361317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018542754A Active JP6949856B2 (ja) 2016-02-16 2017-02-15 5−アミノ−2,3−ジヒドロフタラジン−1,4−ジオンの結晶形の製造方法

Country Status (8)

Country Link
US (1) US11203575B2 (enExample)
EP (1) EP3416952B1 (enExample)
JP (1) JP6949856B2 (enExample)
KR (1) KR102535959B1 (enExample)
CN (1) CN109071461B (enExample)
CA (1) CA3011766C (enExample)
ES (1) ES2796476T3 (enExample)
WO (1) WO2017140422A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
US20210379063A1 (en) * 2018-10-26 2021-12-09 Immunopharma Plus D.O.O. Oral aminodihydrophthalazinedione compositions and their use in the treatment of non-viral hepatitis
EP3858328A1 (en) * 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
ES3057259T3 (en) * 2020-03-25 2026-02-27 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for treatment of acute lung injury
ES3057264T3 (en) * 2020-06-10 2026-02-27 Metriopharm Ag 5-amino-2,3-dihydro-1,4-phthalazinedione for use in the treatment of coronaviral infections
CN116528901A (zh) * 2020-12-01 2023-08-01 瑞沃斯帕有限责任公司 用于治疗慢性阻塞性肺病、哮喘、肺炎、支气管炎、囊性纤维化和肺水肿的方法和组合物
WO2022117221A1 (en) * 2020-12-02 2022-06-09 Metriopharm Ag Luminol for the prophylaxis and the treatment of sequelae of a sars-cov-2 infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743541A (en) * 1985-07-17 1988-05-10 Mast Immunosystems, Inc. Luminescent substrate preparation and its use in specific binding assays
FR2839155B1 (fr) * 2002-04-25 2005-02-04 Roc Imp Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang
BRPI0307864B1 (pt) * 2003-11-25 2016-01-12 Univ Rio De Janeiro processo para formação de hidrazidas a partir de hidrazinas e ácido dicarboxílicos
CN100390152C (zh) * 2006-03-23 2008-05-28 潘健 一种合成3-硝基或3-氨基邻苯二甲酰肼的方法
PL231885B1 (pl) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
CN102971300B (zh) * 2010-03-01 2016-03-02 梅特里奥药品股份公司 5-氨基-2,3-二氢-(2,3-二氮杂萘)-1,4-二酮钠盐的晶型、含有它们的药物制剂以及所述晶型的生产方法
US20110246075A1 (en) * 2010-04-01 2011-10-06 Banik Niranjan C Providing a Transform Function to Produce a Mechanical Property of a Subterranean Structure
WO2011123776A2 (en) * 2010-04-01 2011-10-06 Guthery B Eugene Method for detecting occult blood

Similar Documents

Publication Publication Date Title
JP2019504865A5 (enExample)
JP2018024682A5 (enExample)
JP2015063536A5 (enExample)
JP2013049690A5 (enExample)
JP2014221842A5 (enExample)
JP2015044837A5 (enExample)
JP2010533203A5 (enExample)
JP2021530565A5 (enExample)
JP2018505199A5 (enExample)
JP2018520178A5 (enExample)
JP2019504103A5 (enExample)
JP2009531465A5 (enExample)
JP2019505533A5 (enExample)
JP2012176989A5 (enExample)
JP2012180345A5 (enExample)
RU2016118796A (ru) Новая кристаллическая форма 2-{ 3-[2-(1-{ [3, 5-бис(дифторметил)-1н-пиразол-1-ил]ацетил} пиперидин-4-ил)-1, 3-тиазол-4-ил]-4, 5-дигидро-1, 2-оксазол-5-ил} -3-хлорфенилметансульфоната
JP2014520848A5 (enExample)
JP2018516946A5 (enExample)
CN111386268A (zh) 一种urat1抑制剂的晶型及其制备方法
CN107254055B (zh) 一种直接从等规聚1-丁烯本体中结晶生成i晶的方法
JP2013503145A5 (enExample)
JP2018009003A5 (enExample)
CN111417633A (zh) 一种β-内酰胺酶抑制剂的晶型及其制备方法
CN105315258A (zh) 富马酸沃诺拉赞多晶型及其制备方法
JP2022135397A5 (enExample)